Journal: Smart Materials in Medicine

Article Title: Platinum nanoparticles enhance osteogenic differentiation of human dental follicle stem cells via scavenging ROS

doi: 10.1016/j.smaim.2023.06.004

Figure Lengend Snippet: Fig. 2. Isolation and characterization of hDFSCs. (A) Scheme for isolating and culturing hDFSCs. (B) Panoramic radiograph of dental follicle in human. (C) Image of extracted dental follicle. (D) Representative micrographs depicting the morphology of hDFSCs, scale bar: 100 μm. (E) Flow cytometric analysis of surface markers in hDFSCs, CD29-FITC, CD44-FITC, CD90-PE, CD117-PE, CD31-APC. (F) Immunofluorescence staining of Vimentin and Cytokeratin-14 in hDFSCs. Scale bars: 50 μm. (G) Osteogenic differentiation and adipogenic differentiation of hDFSCs. (a: Representative image of alkaline phosphatase (ALP) staining, scale bar: 250 μm; b: Repre- sentative image of alizarin red s (ARS) staining, scale bar: 250 μm; c: Representative image of oil red o staining, scale bar: 100 μm.

Article Snippet: 1 (continued ) Type Antibody Catalogue number Working dilution Company PE AntiHuman CD117 E-ABF1150D Elabscience (Wuhan, China) FITC Mouse IgG1, κ Isotype Control E-ABF09792C 1:20 Elabscience (Wuhan, China) PE Mouse IgG1, κ Isotype Control E-ABF09792D 1:20 Elabscience (Wuhan, China) APC Mouse IgG1, κ Isotype Control E-ABF09792E 1:20 Elabscience (Wuhan, China) CRediT authorship contribution statement Zheng Wang: Investigation, Writing – original draft.

Techniques: Isolation, Staining

Journal: Cancer Science

Article Title: Activity of triptolide against human mast cells harboring the kinase domain mutant KIT

doi: 10.1111/j.1349-7006.2009.01159.x

Figure Lengend Snippet: Triptolide potently abrogates the growth of cells and decreases KIT expression in xenografts of human mast cells carrying D816V KIT. BALB/c nu/nu nude mice bearing s.c.‐innoculated HMC‐1.2 xenografts were randomized into two groups (10 animals each) for treatment with DMSO containing medium (control) or triptolide 0.15 mg/kg/day. The tumor growth curves are plotted (a). The vertical axis represents the tumor size, and the horizontal axis represents the number of days since triptolide treatment began. Error bars, SE. Images for one representative mouse from each group are shown (b). On day 21, tumor xenografts in mice were dissected and measured. The bar chart (c) shows the weight of the tumors from each group (n = 10). Error bars, SE. *P < 0.0001 by Student's t‐test. (d) The expression of KIT was greatly inhibited by triptolide. Immnunohistochemical analysis with anti‐CD117 antibody (KIT) and H&E in xenograft tissues from mice on day 21 after triptolide treatment.

Article Snippet: Antibodies and their sources were as follows: rabbit polyclonal antibodies against Bax, Mcl‐1 (S‐19), KIT (c‐19), phospho‐KIT on Y568/570, were from Santa Cruz Biotechnology (Santa Cruz, CA, US); antibodies against poly(adenosine diphosphate [ADP]‐ribose) polymerase (PARP), p27Kip1 and p53, Becton‐Dickson Biosciences Pharmingen (San Jose, CA, US); antibodies against phospho‐Erk1/2 (T202/Y204), Erk1/2, Akt, JNK, and XIAP were from Cell Signaling Technology (Beverly, MA, US); mouse monoclonal antibody specific against phosphotyrosine 705 of Stat3 (clone 9E12) and rabbit polyclonal anti‐Stat3, Upstate Technology (Lake Placid, NY, US); mouse anti‐human‐KIT (CD117) monoclonal antibody, R&D Systems (Minneapolis, MN, US); mouse monoclonal antibody against actin, Sigma‐Aldrich (Shanghai, China); rabbit anti‐human RNA polymerase II, phospho‐RNA polymerase II (S5), Bethyl Laboratories (Montgomery, TX, US); and anti‐mouse IgG and anti‐rabbit IgG horseradish peroxidase‐conjugated antibodies, Pierce Biotechnology (Rockford, IL, US).

Techniques: Expressing, Control